The maturation of antibody technology for the HIV epidemic

Immunology and Cell Biology

Volumn 92, Issue 7, 2014, Pages 570-577

  Winnall, Wendy R ^a   Beasley, Matthew D ^b   Center, Rob J ^a,c   Parsons, Matthew S ^a   Kiefel, Ben R ^b   Kent, Stephen J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Small Technologies Cluster   (Australia)

^c BURNET INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY FRAGMENT; BISPECIFIC ANTIBODY; BROADLY NEUTRALIZING ANTIBODY; FC RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; NANOBODY; POLYCLONAL ANTIBODY; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; IMMUNOGLOBULIN FC FRAGMENT; RECOMBINANT PROTEIN;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY SCREENING; ANTIVIRAL THERAPY; EPIDEMIC; EUKARYOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; IN VITRO STUDY; INFECTION PREVENTION; MEDICAL TECHNOLOGY; NONHUMAN; PROKARYOTE; RESEARCH; REVIEW; VIRUS IMMUNITY; VIRUS TRANSMISSION; ANIMAL; BIOTECHNOLOGY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; TRANSMISSION; TRENDS;

ANIMALS; ANTIBODIES, BISPECIFIC; BIOTECHNOLOGY; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; RECOMBINANT PROTEINS; SINGLE-DOMAIN ANTIBODIES;

EID: 84906056947     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2014.35     Document Type: Review

References (104)

1. Rob Aggarwal S. What's fueling the biotech engine-2012 to 2013. Nat Biotechnol 2014; 32: 32-39.
2. Drucker A, Skedgel C, Virik K, Rayson D, Sellon M, Younis T. The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada. Curr Oncol 2008; 15: 136-142.
3. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013; 503: 224-228.
4. Horwitz JA, Halper-Stromberg A, Mouquet H, Gitlin AD, Tretiakova A, Eisenreich TR et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci USA 2013; 110: 16538-16543.
5. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012; 492: 118-122.
6. Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013; 503: 277-280.
7. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11: 615-622. (Pubitemid 40868301)
8. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323-327. (Pubitemid 18091075)
9. Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: The initial results of five trials. Ann Rheum Dis 2002; 61(Suppl 2): Ii70-ii73. (Pubitemid 35221720)
10. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21: 309-318. (Pubitemid 29157789)
11. Sigal LH. Basic science for the clinician 58: IgG subclasses. J Clin Rheumatol 2012; 18: 316-318.
12. Correia IR. Stability of IgG isotypes in serum. MAbs 2010; 2: 221-232.
13. Harel Inbar N, Benhar I. Selection of antibodies from synthetic antibody libraries. Arch Biochem Biophys 2012; 526: 87-98.
14. Better M, Chang CP, Robinson RR, Horwitz AH. Escherichia coli secretion of an active chimeric antibody fragment. Science 1988; 240: 1041-1043.
15. Rivkin A. Certolizumab pegol for the management of Crohn's disease in adults. Clin Ther 2009; 31: 1158-1176.
16. Frey G, Chen J, Rits-Volloch S, Freeman MM, Zolla-Pazner S, Chen B. Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nat Struct Mol Biol 2010; 17: 1486-1491.
17. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011; 333: 1593-1602.
18. Liu Y, Regula LK, Stewart A, Lai J.R. Synthetic Fab fragments that bind the HIV-1 gp41 heptad repeat regions. Biochem Biophys Res Commun 2011; 413: 611-615.
19. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN et al. Protein engineering of antibody binding sites: Recovery of specific activity in an antidigoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 1988; 85: 5879-5883.
20. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM et al. Singlechain antigen-binding proteins. Science 1988; 242: 423-426.
21. Frenzel A, Hust M, Schirrmann T. Expression of recombinant antibodies. Frontiers Immunol 2013; 4: 217.
22. Byrne H, Conroy PJ, Whisstock JC, O'Kennedy RJ. A tale of two specificities: Bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 2013; 31: 621-632.
23. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25: 1290-1297. (Pubitemid 350076510)
24. LaFleur DW, Abramyan D, Kanakaraj P, Smith RG, Shah RR, Wang G et al. Monoclonal antibody therapeutics with up to five specificities: Functional enhancement through fusion of target-specific peptides. MAbs 2013; 5: 208-218.
25. Spiess C, Merchant M, Huang A, Zheng Z, Yang NY, Peng J et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol 2013; 31: 753-758.
26. Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA. BiTEs: Bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 2005; 10: 1237-1244. (Pubitemid 41411434)
27. Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 2013; 17: 385-392.
28. Muyldermans S. Nanobodies: Natural single-domain antibodies. Annu Rev Biochem 2013; 82: 775-797.
29. Caljon G, Caveliers V, Lahoutte T, Stijlemans B, Ghassabeh GH, Van Den Abbeele J et al. Using microdialysis to analyse the passage of monovalent nanobodies through the blood-brain barrier. Br J Pharmacol 2012; 165: 2341-2453.
30. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011; 22: 868-876.
31. Reichert JM. Antibodies to watch in 2013: Mid-year update. MAbs 2013; 5: 513-517.
32. Marichal-Gallardo PA, Alvarez MM. State-of-the-art in downstream processing of monoclonal antibodies: Process trends in design and validation. Biotechnol Prog 2012; 28: 899-916.
33. Choi BK, Bobrowicz P, Davidson RC, Hamilton SR, Kung DH, Li H et al. Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris. Proc Natl Acad Sci USA 2003; 100: 5022-5027. (Pubitemid 36546252)
34. Lotter-Stark HC, Rybicki EP, Chikwamba RK. Plant made anti-HIV microbicides-A field of opportunity. Biotechnol Adv 2012; 30: 1614-1626.
35. Proba K, Worn A, Honegger A, Pluckthun A. Antibody scFv fragments without disulfide bonds made by molecular evolution. J Mol Biol 1998; 275: 245-253. (Pubitemid 28030002)
36. Lloyd SB, Kent SJ, Winnall WR. The high cost of fidelity. AIDS Res Hum Retroviruses 2014; 30: 8-16.
37. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003; 100: 4144-4149. (Pubitemid 36418171)
38. Wibmer CK, Bhiman JN, Gray ES, Tumba N, Abdool Karim SS, Williamson C et al. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog 2013; 9: E1003738.
39. Eroshkin AM, Leblanc A, Weekes D, Post K, Li Z, Rajput A et al. bNAber: Database of broadly neutralizing HIV antibodies. Nucleic Acids Res 2014; 42: D1133-D1139.
40. Kwong PD, Mascola J.R. Human antibodies that neutralize HIV-1: Identification, structures, and B cell ontogenies. Immunity 2012; 37: 412-425.
41. Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012; 337: 183-186.
42. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73: 4009-4018. (Pubitemid 29189846)
43. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6: 207-210. (Pubitemid 30082367)
44. Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482: 89-93.
45. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010; 467: 591-595.
46. Verkoczy L, Diaz M, Holl TM, Ouyang YB, Bouton-Verville H, Alam SM et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci USA 2010; 107: 181-186.
47. Finton KA, Larimore K, Larman HB, Friend D, Correnti C, Rupert PB et al. Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10. PLoS Pathog 2013; 9: E1003639.
48. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, Dekosky BJ et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014; 509: 55-62.
49. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329: 856-861.
50. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011; 333: 1633-1637.
51. Zhou T, Zhu J, Wu X, Moquin S, Zhang B, Acharya P et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 2013; 39: 245-258.
52. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266: 1024-1027. (Pubitemid 24373715)
53. Kessler JA 2nd, McKenna PM, Emini EA, Chan CP, Patel MD, Gupta SK et al. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses 1997; 13: 575-582. (Pubitemid 27190565)
54. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994; 68: 4821-4828. (Pubitemid 24226546)
55. Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, Gray E et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 2011; 85: 9998-10009.
56. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477: 466-470.
57. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326: 285-289.
58. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013; 496: 469-476.
59. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999; 5: 204-210. (Pubitemid 29068528)
60. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6: 200-206. (Pubitemid 30082366)
61. Armbruster C, Stiegler GM, Vcelar BA, Jager W, Michael NL, Vetter N et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 2002; 16: 227-233. (Pubitemid 34118570)
62. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010; 84: 1302-1313.
63. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, Wang T, Xu W, Li PL et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 2003; 17: 301-309. (Pubitemid 36223254)
64. Mascola JR, Louder MK, VanCott TC, Sapan CV, Lambert JS, Muenz LR et al. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J Virol 1997; 71: 7198-7206. (Pubitemid 27391653)
65. Vijh-Warrier S, Pinter A, Honnen WJ, Tilley SA. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site. J Virol 1996; 70: 4466-4473.
66. Li A, Baba TW, Sodroski J, Zolla-Pazner S, Gorny MK, Robinson J et al. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res Hum Retroviruses 1997; 13: 647-656. (Pubitemid 27210453)
67. Bregenholt S, Jensen A, Lantto J, Hyldig S, Haurum JS. Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections. Curr Pharm Des 2006; 12: 2007-2015. (Pubitemid 43821689)
68. Jacobson JM, Lalezari JP, Thompson MA, Fichtenbaum CJ, Saag MS, Zingman BS et al. Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrob Agents Chemother 2010; 54: 4137-4142.
69. Berg J, Lotscher E, Steimer KS, Capon DJ, Baenziger J, Jack HM et al. Bispecific antibodies that mediate killing of cells infected with human immunodeficiency virus of any strain. Proc Natl Acad Sci USA 1991; 88: 4723-4727. (Pubitemid 21914614)
70. Traunecker A, Lanzavecchia A, Karjalainen K. Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells. EMBO J 1991; 10: 3655-3659. (Pubitemid 21905391)
71. Chamow SM, Zhang DZ, Tan XY, Mhatre SM, Marsters SA, Peers DH et al. A humanized, bispecific immunoadhesin-antibody that retargets CD3\+ effectors to kill HIV-1-infected cells. J Immunol 1994; 153: 4268-4280.
72. Mukhtar M, Parveen Z, Pomerantz RJ. Technology evaluation: PRO-542, Progenics Pharmaceuticals inc. Curr Opin Mol Ther 2000; 2: 697-702. (Pubitemid 32063105)
73. Mabondzo A, Boussin F, Raoul H, Le Naour R, Gras G, Vaslin B et al. Antibodydependent cellular cytotoxicity and neutralization of human immunodeficiency virus type 1 by high affinity cross-linking of gp41 to human macrophage Fc IgG receptor using bispecific antibody. J Gen Virol 1994; 75: 1451-1456. (Pubitemid 24174062)
74. Howell AL, Guyre PM, You K, Fanger MW. Targeting HIV-1 to Fc gamma R on human phagocytes via bispecific antibodies reduces infectivity of HIV-1 to T cells. J Leukoc Biol 1994; 55: 385-391. (Pubitemid 24097246)
75. Schanzer J, Jekle A, Nezu J, Lochner A, Croasdale R, Dioszegi M et al. Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains. Antimicrob Agents Chemother 2011; 55: 2369-2378.
76. Bruhl H, Cihak J, Stangassinger M, Schlondorff D, Mack M. Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: A new strategy in the treatment of chronic inflammatory diseases and HIV. J Immunol 2001; 166: 2420-2426. (Pubitemid 32173477)
77. Pace CS, Song R, Ochsenbauer C, Andrews CD, Franco D, Yu J et al. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc Natl Acad Sci USA 2013; 110: 13540-13545.
78. Jia L, Xu Y, Zhang C, Wang Y, Chong H, Qiu S et al. A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complement. Virol J 2010; 7: 142.
79. Duval M, Posner MR, Cavacini LA. A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils. J Virol 2008; 82: 4671-4674. (Pubitemid 351563705)
80. Matz J, Kessler P, Bouchet J, Combes O, Ramos OH, Barin F et al. Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. J Virol 2013; 87: 1137-1149.
81. McCoy LE, Quigley AF, Strokappe NM, Bulmer-Thomas B, Seaman MS, Mortier D et al. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J Exp Med 2012; 209: 1091-1103.
82. Lutje Hulsik D, Liu YY, Strokappe NM, Battella S, El Khattabi M, McCoy LE et al. A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition. PLoS Pathol 2013; 9: E1003202.
83. Forsman A, Beirnaert E, Aasa-Chapman MM, Hoorelbeke B, Hijazi K, Koh W et al. Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol 2008; 82: 12069-12081.
84. Acharya P, Luongo TS, Georgiev IS, Matz J, Schmidt SD, Louder MK et al. Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor-and CD4-binding sites. J Virol 2013; 87: 10173-10181.
85. Gorlani A, Brouwers J, McConville C, van der Bijl P, Malcolm K, Augustijns P et al. Llama antibody fragments have good potential for application as HIV type 1 topical microbicides. AIDS Res Hum Retroviruses 2012; 28: 198-205.
86. Nadkarni A, Kelley LL, Momany C. Optimization of a mouse recombinant antibody fragment for efficient production from Escherichia coli. Protein Expr Purif 2007; 52: 219-229. (Pubitemid 46038761)
87. Palmberger D, Rendic D, Tauber P, Krammer F, Wilson IB, Grabherr R. Insect cells for antibody production: Evaluation of an efficient alternative. J Biotechnol 2011; 153: 160-166.
88. Mader A, Prewein B, Zboray K, Casanova E, Kunert R. Exploration of BAC versus plasmid expression vectors in recombinant CHO cells. Appl Microbiol Biotechnol 2013; 97: 4049-4054.
89. Kramski M, Center RJ, Wheatley AK, Jacobson JC, Alexander MR, Rawlin G et al. Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides. Antimicrob Agents Chemother 2012; 56: 4310-4319.
90. Dorosko SM, Ayres SL, Connor RI. Induction of HIV-1 MPR(649-684)-specific IgA and IgG antibodies in caprine colostrum using a peptide-based vaccine. Vaccine 2008; 26: 5416-5422.
91. Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011; 477: 95-98.
92. Malbec M, Porrot F, Rua R, Horwitz J, Klein F, Halper-Stromberg A et al. Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. J Exp Med 2013; 210: 2813-2821.
93. Klein K, Veazey RS, Warrier R, Hraber P, Doyle-Meyers LA, Buffa V et al. Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge. J Virol 2013; 87: 11604-11616.
94. Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9: 343-346. (Pubitemid 36362791)
95. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75: 8340-8347. (Pubitemid 32743706)
96. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449: 101-104. (Pubitemid 47373775)
97. Tramontano A, Bianchi E, Venturini S, Martin F, Pessi A, Sollazzo M. The making of the minibody: An engineered beta-protein for the display of conformationally constrained peptides. J Mol Recognit: JMR 1994; 7: 9-24. (Pubitemid 2122641)
98. Baudino L, Shinohara Y, Nimmerjahn F, Furukawa J, Nakata M, Martinez-Soria E et al. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J Immunol 2008; 181: 6664-6669.
99. Greenwood J, Clark M, Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 1993; 23: 1098-1104. (Pubitemid 23120172)
100. Abdel-Motal UM, Sarkis PT, Han T, Pudney J, Anderson DJ, Zhu Q et al. Anti-gp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge in vitro. PLoS ONE 2011; 6: E26473.
101. Chancey CJ, Khanna KV, Seegers JF, Zhang GW, Hildreth J, Langan A et al. Lactobacilli-expressed single-chain variable fragment (scFv) specific for intercellular adhesion molecule 1 (ICAM-1) blocks cell-associated HIV-1 transmission across a cervical epithelial monolayer. J Immunol 2006; 176: 5627-5636.
102. Lagenaur LA, Sanders-Beer BE, Brichacek B, Pal R, Liu X, Liu Y et al. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol 2011; 4: 648-657.
103. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009; 15: 901-906.
104. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012; 481: 81-84.